Logo image of INMB

INMUNE BIO INC (INMB) Stock Fundamental Analysis

NASDAQ:INMB - Nasdaq - US45782T1051 - Common Stock - Currency: USD

2.74  +0.05 (+1.86%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to INMB. INMB was compared to 551 industry peers in the Biotechnology industry. While INMB seems to be doing ok healthwise, there are quite some concerns on its profitability. INMB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INMB had negative earnings in the past year.
In the past year INMB has reported a negative cash flow from operations.
In the past 5 years INMB always reported negative net income.
In the past 5 years INMB always reported negative operating cash flow.
INMB Yearly Net Income VS EBIT VS OCF VS FCFINMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -107.92%, INMB is doing worse than 78.04% of the companies in the same industry.
With a Return On Equity value of -137.49%, INMB is not doing good in the industry: 60.80% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -107.92%
ROE -137.49%
ROIC N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
INMB Yearly ROA, ROE, ROICINMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

INMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INMB Yearly Profit, Operating, Gross MarginsINMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for INMB has been increased compared to 1 year ago.
INMB has more shares outstanding than it did 5 years ago.
INMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INMB Yearly Shares OutstandingINMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
INMB Yearly Total Debt VS Total AssetsINMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

INMB has an Altman-Z score of -4.33. This is a bad value and indicates that INMB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INMB (-4.33) is comparable to the rest of the industry.
There is no outstanding debt for INMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.33
ROIC/WACCN/A
WACCN/A
INMB Yearly LT Debt VS Equity VS FCFINMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

INMB has a Current Ratio of 2.64. This indicates that INMB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of INMB (2.64) is worse than 68.42% of its industry peers.
A Quick Ratio of 2.64 indicates that INMB has no problem at all paying its short term obligations.
With a Quick ratio value of 2.64, INMB is not doing good in the industry: 66.61% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.64
Quick Ratio 2.64
INMB Yearly Current Assets VS Current LiabilitesINMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

INMB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.52%.
Looking at the last year, INMB shows a very negative growth in Revenue. The Revenue has decreased by -62.12% in the last year.
INMB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -57.31% yearly.
EPS 1Y (TTM)-0.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.51%
Revenue 1Y (TTM)-62.12%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%257.14%

3.2 Future

INMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.79% yearly.
The Revenue is expected to grow by 572.34% on average over the next years. This is a very strong growth
EPS Next Y24.83%
EPS Next 2Y15.38%
EPS Next 3Y11.43%
EPS Next 5Y18.79%
Revenue Next Year308.19%
Revenue Next 2Y1948.89%
Revenue Next 3Y968.69%
Revenue Next 5Y572.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INMB Yearly Revenue VS EstimatesINMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
INMB Yearly EPS VS EstimatesINMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INMB Price Earnings VS Forward Price EarningsINMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INMB Per share dataINMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.38%
EPS Next 3Y11.43%

More info and screens

0

5. Dividend

5.1 Amount

INMB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMUNE BIO INC

NASDAQ:INMB (8/6/2025, 2:20:59 PM)

2.74

+0.05 (+1.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07
Inst Owners25.51%
Inst Owner Change-8.39%
Ins Owners20.07%
Ins Owner Change0%
Market Cap72.86M
Analysts78.18
Price Target11.66 (325.55%)
Short Float %27.62%
Short Ratio1.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.84%
Min EPS beat(2)10.3%
Max EPS beat(2)27.38%
EPS beat(4)3
Avg EPS beat(4)10.36%
Min EPS beat(4)-18.44%
Max EPS beat(4)27.38%
EPS beat(8)4
Avg EPS beat(8)2.1%
EPS beat(12)7
Avg EPS beat(12)-130.55%
EPS beat(16)9
Avg EPS beat(16)-99.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-51.14%
PT rev (3m)-51.14%
EPS NQ rev (1m)5.99%
EPS NQ rev (3m)15.93%
EPS NY rev (1m)9.59%
EPS NY rev (3m)13.52%
Revenue NQ rev (1m)-16.5%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)71.44%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1457.13
P/FCF N/A
P/OCF N/A
P/B 2.46
P/tB 5.54
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0
BVpS1.12
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.92%
ROE -137.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.13%
ROA(5y)-50.5%
ROE(3y)-85.07%
ROE(5y)-64.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.64
Quick Ratio 2.64
Altman-Z -4.33
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.51%
EPS Next Y24.83%
EPS Next 2Y15.38%
EPS Next 3Y11.43%
EPS Next 5Y18.79%
Revenue 1Y (TTM)-62.12%
Revenue growth 3Y-57.31%
Revenue growth 5YN/A
Sales Q2Q%257.14%
Revenue Next Year308.19%
Revenue Next 2Y1948.89%
Revenue Next 3Y968.69%
Revenue Next 5Y572.34%
EBIT growth 1Y-20.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-118.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.64%
OCF growth 3YN/A
OCF growth 5YN/A